Franklin, Tenn.-based M*Modal develops cloud-based, conversational artificial intelligence-powered software platforms. The company’s products are intended to allow physicians to “capture and improve the patient narrative,” to allow them to gain more face time with the patient and improve quality of care, St. Paul, Minn.-based 3M said.
Annual revenue for M*Modal’s tech business is estimated at approximately $200 million, 3M said in a press release. The company added that it plans to integrate the newly acquired tech into its health information systems.
3M said that the financial impact of the buy was included in its recently reported full-year 2019 guidance.
Shares in 3M have dropped 1.3% today, at $196.53 as of 10:55 a.m. EST.
Late last month, 3M reported flat fourth quarter profits for its healthcare business, but saw them rise overall for the year as it posted consensus-topping earnings for its last quarter and full 2018 year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.